NGL Fine-Chem Limited

NSE NGLFINE.NS

NGL Fine-Chem Limited EBITDA Margin for the year ending March 31, 2024: 20.04%

NGL Fine-Chem Limited EBITDA Margin is 20.04% for the year ending March 31, 2024, a 37.63% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

NGL Fine-Chem Limited EBITDA Margin for the year ending March 31, 2023 was 14.56%, a -42.26% change year over year.
NGL Fine-Chem Limited EBITDA Margin for the year ending March 31, 2022 was 25.21%, a -27.04% change year over year.
NGL Fine-Chem Limited EBITDA Margin for the year ending March 31, 2021 was 34.56%, a 125.68% change year over year.
NGL Fine-Chem Limited EBITDA Margin for the year ending March 31, 2020 was 15.31%, a -36.14% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NSE: NGLFINE.NS

NGL Fine-Chem Limited

CEO	Mr. Rahul Jayant Nachane
IPO Date	July 8, 2022
Location	India
Headquarters	301, E Square
Employees	682
Sector	Health Care
Industries Pharmaceuticals

Description

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. It offers active pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, and marbofloxacin for animal health applications; and nitazoxanide, atovaquone, and ranolazine for human health applications. The company also provides various intermediate products; and finished dosage forms in granules and tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.

Key trends

Past 5 years